Stay tuned and follow the latest
developments and news in Molecular Oncology.
We are proud to announce that Genekor Medical S.A. was honored with the Business Partner of the Year 2024 award at the recent Exact Sciences annual event in Rome. This […]
Read More
#DressinBlueDay Wearing blue this month has a special meaning for us at GeneKor. Blue is the color of support for those affected by colorectal cancer, one of the most common […]
Read More
The innovative prime DX® technology is compatible with both FFPET and PLASMA, offering a comprehensive approach to personalized cancer treatment. With 1,021 genes, including over 30 related to homologous recombination […]
Read More
NICE diagnostics guidance – evaluation of effectiveness and efficiency The NICE (National Institute for Health and Care Excellence) diagnostics guidance DG58 givesevidence-based recommendations to guide treatment decisions and evaluate the […]
Read More
This year, our team attended the San Antonio Breast Cancer Symposium (SABCS) in Texas, a key event in breast cancer research. It was a great opportunity to connect with healthcare […]
Read More
Source: Iatronet Nikolaos Tsoulos, MBA, PhD, Molecular Biochemist, CEO of GeneKor Medical SA, and Chairman of the Hellenic Society of Diagnostic Laboratories (EDEM), spoke to Iatronet about accredited diagnostic laboratories […]
Read More
Dr. George Nasioulas, Scientific Director of Genekor Medical S.A. and Molecular Biologist, PhD gave an interview on Shape.gr about liquid biopsies and how they change the prognosis of pancreatic cancer. Pancreatic […]
Read More
Genekor’s Pathology Laboratory now offers the Claudin 18.2 (CLDN 18.2) test, used to administer Zolbetuximab in combination with chemotherapy for patients with advanced or metastatic gastric adenocarcinoma and gastroesophageal junction […]
Read More
The FRα test is performed for the administration of mirvetuximab soravtansine and is aimed at patients with platinum-resistant ovarian cancer who are FRα-positive and have received 1-3 lines of therapy. […]
Read More